Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

To get information on brands we work on currently or could potentially work on

— Marketing professional, USA

To learn about drugs that will be coming off patent and to offer an ANDA in their master drug file

— Global market development manager, healthcare packaging provider, USA

To identify pharmaceutical product patents and process patents, and drug patent expiries

— Global pharmaceutical regulatory affairs, India

To get information on patent expiration dates, in particular composition patents

— Private equity, USA

To analyze generic candidates using patent expiration data

— Portfolio management, Indonesia

Generated: May 27, 2017

DrugPatentWatch Database Preview

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9% Drug Profile

« Back to Dashboard

What is the patent landscape for Heparin Sodium 12,500 Units In Sodium Chloride 0.9%, and when can generic versions of Heparin Sodium 12,500 Units In Sodium Chloride 0.9% launch?

Heparin Sodium 12,500 Units In Sodium Chloride 0.9% is a drug marketed by Hospira and is included in two NDAs.

The generic ingredient in HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9% is heparin sodium. There are seventy-six drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the heparin sodium profile page.

Summary for Tradename: HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%

Patents:0
Applicants:1
NDAs:2
Suppliers / Packagers: see list1
Clinical Trials: see list2,554
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9% at DailyMed

Pharmacology for Tradename: HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%

Ingredient-typeHeparin
Drug ClassAnti-coagulant
Unfractionated Heparin
ADD ALERT
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hospira
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%
heparin sodium
INJECTABLE;INJECTION018911-005Jan 30, 1985DISCNNoNo► Subscribe► Subscribe
Hospira
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%
heparin sodium
INJECTABLE;INJECTION018916-003Jan 31, 1984DISCNNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Analyze global market entry opportunities
  • Formulary management
  • Identify first generic entrants

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Patent expiration dates for current drugs on market, especially drugs that target the Central Nervous System.

— Business development for a clinical trial research site, USA

To explore which pharmaceutical products are still under patent protection

— Managing partner for pharmaceutical company, Lebanon

To review patents of pharmaceutical products

— Pharmaceutical regulatory affairs, India

To get a list of drugs going off patent in USA in the next few years

— Pharmaceutical sales, India

To find all manufacturers of a drug with active DMFs

— CEO, specialty pharmaceutical firm, USA

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Related Products from thinkBiotech
Links

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot